Kymera Therapeutics Q1 Revenue Jumps 55% to $34.4M, Advances Key Clinical Programs
KYMR has more than doubled off its 52-week low of $28.06.
Summary
Kymera Therapeutics reported its first-quarter 2026 results, showing a significant 55.5% year-over-year increase in revenue to $34.4 million, primarily driven by collaboration revenue from the Gilead agreement. While the company's net loss widened slightly to $69.2 million, diluted loss per share improved to $(0.71) from $(0.82) in the prior year. The report also highlighted substantial clinical progress, with the STAT6 (KT-621) program advancing into Phase 2b trials and the IRF5 (KT-579) program in Phase 1. Strategic partnerships continue to progress, including Gilead licensing KT-200 and Sanofi advancing the IRAK4 degrader. The company maintains a strong liquidity position with approximately $1.55 billion in cash and marketable securities, expected to fund operations into 2029. This earnings report provides critical updates on both financial performance and pipeline development, which are key drivers for a clinical-stage biotech. Traders will be watching for further clinical trial readouts and partnership milestones.
At the time of this announcement, KYMR was trading at $83.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $28.06 to $103.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.